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The combination of a natural polymer poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
(PHBV) and a synthetic hydrophobic polymer poly(ε-caprolactone) (PCL) is promising
for the preparation of biodegradable and biocompatible small-diameter vascular grafts
for bypass surgery. However, physico-mechanical properties and endothelialization rate
of PHBV/PCL grafts are poor. We suggested that incorporation of vascular endothelial
growth factor (VEGF) into PHBV/PCL grafts may improve their physico-mechanical
properties and enhance endothelialization. Here we compared morphology, physico-
mechanical properties, and in vivo performance of electrospun small-diameter vascular
grafts prepared from PHBV/PCL with and without VEGF. Structure of the graft surface
and physico-mechanical properties were examined by scanning electron microscopy
and universal testing machine, respectively. Grafts were implanted into rat abdominal
aorta for 1, 3, and 6 months with the further histological, immunohistochemical,
and immunofluorescence examination. PHBV/PCL grafts with and without VEGF were
highly porous and consisted mostly of nanoscale and microscale fibers, respectively.
Mean pore diameter and mean pore area were significantly lower in PHBV/PCL/VEGF
compared to PHBV/PCL grafts (1.47 µm and 10.05 µm2; 2.63 µm and 47.13 µm2,
respectively). Durability, elasticity, and stiffness of PHBV/PCL grafts with VEGF were
more similar to internal mammary artery compared to those without, particularly
6 months postimplantation. Both qualitative examination and quantitative image analysis
showed that three-fourths of PHBV/PCL grafts with VEGF were patent and had many
CD31-, CD34-, and vWF-positive cells at their inner surface.
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However, all PHBV/PCL grafts without VEGF were occluded and had no or a few CD31-
positive cells at the inner surface. Therefore, VEGF enhanced endothelialization and
improved graft patency at all the time points in a rat abdominal aorta replacement model.
In conclusion, PHBV/PCL grafts with VEGF have better biocompatibility and physico-
mechanical properties compared to those without. Incorporation of VEGF improves graft
patency and accelerates formation of endothelial cell monolayer.
Keywords: poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(ε-caprolactone), vascular endothelial growth
factor, vascular graft, morphology, physico-mechanical properties, endothelialization, patency
INTRODUCTION
Reconstructive surgery is a conventional treatment of coronary
artery disease and peripheral artery disease, and autologous
saphenous vein (SV), internal mammary and radial artery grafts
are commonly used (Taggart, 2013). However, a significant
proportion of the patients do not have suitable veins or arteries
that could be used (Desai et al., 2011). Therefore, tissue
engineering of vascular grafts is a promising approach for the
replacement of small-diameter (<6 mm) blood vessels (Desai
et al., 2011). Small-diameter vascular grafts can be prepared
from biodegradable polymers and may become a scaffold for the
formation of a blood vessel in situ (Antonova et al., 2015a). The
combination of natural and synthetic polymers was suggested
as improving the properties and resorption rate of the scaffold
(Antonova et al., 2015a).
It was demonstrated that poly(ε-caprolactone) (PCL) may
be successfully used for the preparation of the vascular grafts
(de Valence et al., 2012; Kuwabara et al., 2012). Electrospun
PCL grafts implanted into rat abdominal aorta possessed
structural integrity, patency, and promoted formation of
extracellular matrix 6 months postimplantation (Pektok
et al., 2008). Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
(PHBV) is a natural polymer synthesized by bacteria
as storage compound under growth limiting conditions
(Quillaguamán et al., 2010). One of its monomers, 3-
hydroxybutanoic acid, is a natural metabolite produced in
the human body (Quillaguamán et al., 2010). This ensures a
high biocompatibility of PHBV (Quillaguamán et al., 2010).
According to the previously published data, PHBV/PCL
combination improves biocompatibility of electrospun small-
diameter vascular grafts (Del Gaudio et al., 2012; Antonova et al.,
2015b).
Vascular endothelial growth factor (VEGF) is a key player
in vasculogenesis and angiogenesis, and therefore it is widely
used for the stimulation of graft endothelialization (Maes
et al., 2002). VEGF induces migration, proliferation, and
survival of endothelial cells, enhances nitric oxide production,
and improves vascular permeability (Takahashi et al., 2004).
We previously demonstrated that VEGF incorporated into
electrospun polymer scaffolds retains its biological activity
in vitro (Sevostyanova et al., 2015). Here we compared
morphology, physico-mechanical properties, patency and
endothelialization rate of PHBV/PCL small-diameter vascular
grafts with and without VEGF after the implantation into rat
abdominal aorta.
MATERIALS AND METHODS
Graft Preparation
Small-diameter vascular grafts were prepared by electrospinning
(Nanon-01A, MECC) from PHBV/PCL (1:2, Sigma–
Aldrich)/chloroform solution using the following parameters:
20 kV voltage, 0.3 mL/h feed rate, 2 mm rotating drum diameter,
and 22G needle. VEGF (Sigma–Aldrich) was dissolved in
phosphate buffered saline (PBS) to 10 µg/mL concentration
and then added to PHBV/PCL/chloroform solution (1:20) with
the final concentration of 500 ng/mL. For the preparation of
electrospun PHBV/PCL/VEGF grafts, we used the following
parameters: 23 kV voltage, 0.3 mL/h feed rate, 2 mm rotating
drum diameter, and 27G needle.
Morphological Assessment
PHBV/PCL and PHBV/PCL/VEGF graft samples 0.5 mm
× 0.5 mm (n = 5 per group) were examined using scanning
electron microscopy (Hitachi S-3400N, Hitachi) with Au-Pd
sputter coating (Quorum Technologies) of 30 nm thickness. Fiber
diameter, pore area, and porosity were measured using ImageJ
(National Institutes of Health). Mean fiber diameter and mean
pore area were calculated after at least 100 measurements per each
sample.
Evaluation of Physico-Mechanical
Properties
Assessment of durability and elastic deformation properties
was performed using universal testing machine (Zwick/Roell).
Testing was performed with 1 cm working segment length,
0.01 N preload, and 10 mm/min crosshead speed. Durability,
elasticity, and stiffness were evaluated by yield stress, relative
elongation, and elastic modulus, respectively. We assessed six
vascular grafts per group. Synthetic vascular graft made of
expanded poly(tetrafluoroethylene) (ePTFE, Vascutek), human
SV and internal mammary artery (IMA) (n = 6 per each) were
used as the controls. SV and IMA were collected from patients
who underwent coronary artery bypass graft surgery, and all the
participants provided written informed consent after receiving a
full explanation of the study. The study protocol was approved by
a local ethical committee.
In vivo Implantation
All animal experiments were performed in 6-month-old male
Wistar rats (400–450 g body weight, n = 24) according to
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all official and ethical requirements. Rats were obtained from
the core facility of Research Institute for Complex Issues
of Cardiovascular Diseases. The animals were allocated in
polypropylene cages (five animals per cage) lined with wood
chips and had access to water and food (rat chow) ad libitum.
Throughout the whole time of experiment, standard conditions
of temperature (24 ± 1◦C), relative humidity (55 ± 10%), and
12 h light/dark cycles were carefully maintained, and the health
status of all rats was monitored daily.
After ethylene oxide sterilization, 2 mm diameter and 10 mm
length PHBV/PCL and PHBV/PCL/VEGF (n = 12 per group)
grafts were implanted into rat abdominal aorta after the induction
of anesthesia with 3% isoflurane. During the surgery, all animals
received inhalation anesthesia with 1.5% isoflurane. Briefly, a
midline laparotomy was performed. After the isolation of the
abdominal cavity with a sterile cloth, intestinal loops were
moved to the right and wrapped in a wet warm cloth. The
posterior peritoneal leaflet was opened along the mesenteric
root, and the aorta was mobilized from the level of renal
arteries to bifurcation. Then, aorta was temporarily occluded
with two microvascular bulldog clamps distally from the renal
arteries and proximally from the bifurcation. The aorta and
vena cava inferior were occluded in parallel. Both proximal and
distal anastomoses were performed using Prolene 8-0. Graft was
washed between the performances of these anastomoses. After
the implantation, the anterior abdominal wall was closed layer-
by-layer with a blanket suture (4-0 or 2-0 Vicryl). All procedures
were performed using strict aseptic technique. In each group,
one-third (n = 4) of rats was sacrificed 1, 3, and 6 months
postimplantation.
After the explantation, grafts with the adjacent aortic
tissue were divided into two equal parts (5 mm length
each). The first part was frozen at −140◦C for the further
immunofluorescence staining. The second part was fixed in 10%
(w/v) neutral phosphate buffered formalin (Electron Microscopy
Sciences) during 24 h at 4◦C for the further histological and
immunohistochemical examination.
Histological Examination
After the explantation, formalin-fixed grafts were dehydrated
in isopropanol during 30 h at 4◦C, rinsed in distilled water,
embedded in paraffin (Electron Microscopy Sciences), sectioned
(5 µm), and finally mounted on glass microscope slides.
For a deparaffinization, paraffin-embedded tissue sections were
heated in dry oven at 60◦C for 20 min, immersed in the
following reagents: 3x xylene (Electron Microscopy Sciences)
for 10 min, 100, 95, 70, 50, 30% ethanol for 1 min each,
physiological saline for 2 min, PBS for 2 min, and finally
rinsed with tap water. For hematoxylin and eosin (H&E)
staining, the sections were immersed in Harris Hematoxylin
solution (Electron Microscopy Sciences) for 1 min, rinsed
with tap water, immersed in 1% aqueous Eosin Y solution
(Electron Microscopy Sciences) for 1 min, rinsed with tap water,
dehydrated in ascending ethanol solutions (50, 70, 80, 2x 95%,
and 2x 100%), and then cleared 2x with xylene. Coverslips were
mounted onto a labeled glass slide with Permount (Electron
Microscopy Sciences). After the staining, sections were evaluated
by light microscopy (Axio Imager A1, Carl Zeiss) in a blinded
fashion; three sections per stain were assessed from each
rat.
Immunohistochemistry
For immunohistochemical assessment, we used the kit of
Novocastra (Thermo Scientific) and rabbit anti-CD31 antibodies
(M338, Spring Bioscience) according to manufacturer’s
instructions. Briefly, samples were boiled in citrate buffer
(0.01 M, pH 6.0) for antigen retrieval, treated by the inhibitor
of endogenous peroxidase for 10 min, and washed twice in
phosphate buffer (0.01 M, pH 7.4) for 5 min. For blocking
non-specific background staining, we treated the samples
with Protein Block for 10 min with the further 2x washing in
phosphate buffer for 5 min. Then, we stained the samples with
50 µL of primary anti-CD31 (PECAM-1) antibodies, incubated
them in a wet chamber for 1 h, and performed the staining
with goat anti-rabbit secondary antibodies (12-348, Millipore).
After the washing in phosphate buffer, we treated samples
with streptavidin-peroxidase conjugate and diaminobenzidine
with the further assessment of the reaction which was stopped
by cold distilled water. Slides were then stained with Mayer’s
Hematoxylin and finally mounted. Native blood vessels and
antibody diluent were used as a positive and negative control,
respectively. After the staining, sections were evaluated by
light microscopy (Axio Imager A1, Carl Zeiss) in a blinded
fashion; three sections per stain were assessed from each
rat.
Confocal Laser Scanning Microscopy
Snap-frozen tissue blocks were cut on a cryostat (Microm HM
525, Thermo Scientific), and sections (8 µm) were mounted
on the glass microscope slides. Samples were stained with
unconjugated mouse anti-CD31 (ab119339, Abcam) and rabbit
anti-CD34 (ab185732, Abcam) or fluorescein isothiocyanate
(FITC)-conjugated sheep anti-von Willebrand factor (vWF,
ab8822, Abcam) primary antibodies and incubated at 4◦C for
17 h. Then, in the case of CD31 and CD34 staining, slides
were treated with secondary sheep anti-mouse rhodamine-
conjugated (AP300R, Millipore) and goat anti-rabbit FITC-
conjugated antibodies (12-507, Millipore) with the further
incubation for 1 h at room temperature. Washing was
performed thrice with PBS. Autofluorescence Eliminator Reagent
(Millipore) was used to reduce autofluorescence. If needed,
nuclei were stained with DAPI for 30 min at room temperature
(10 µg/mL, Sigma–Aldrich). Slides were mounted onto a
labeled glass slide with ProLong (Life Technologies). Native
rat aorta was used as a positive control for anti-CD31
and anti-vWF staining whereas rat embryo was used as a
positive control for anti-CD34 staining. Bovine serum albumin
(Sigma) was used instead of the primary antibodies as a
negative control. Visualization was performed using LSM
700 Confocal Laser Scanning Microscope (Carl Zeiss) in a
blinded fashion; three sections per stain were assessed from
each rat. Quantitative image analysis was performed using
ImageJ.
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Statistical Analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software). A sampling distribution was assessed
by D’Agostino-Pearson test and Kolmogorov–Smirnov
test. Depending on the distribution, descriptive data were
represented by median and interquartile range (25th and 75th
percentiles) or mean and standard deviation of the mean.
Two independent groups were compared by Mann–Whitney
U-test or two-tailed Student’s t-test. Independent groups
numbering three or more were compared using Kruskal–Wallis
test or analysis of variance (ANOVA), with pairs further
compared by Mann–Whitney U-test or two-tailed Student’s
t-test if statistically significant differences were revealed by
Kruskal–Wallis test or ANOVA, respectively. An adjustment
for multiple comparisons was performed using false discovery
rate (FDR). P-values, or q-values if FDR was applied (q-values
are the name given to the adjusted p-values found using an
optimized FDR approach), ≤0.05 were regarded as statistically
significant.
RESULTS
Incorporation of VEGF into PHBV/PCL
Vascular Grafts Leads to the Formation
of Nanoscale Fibers and Small Pores
Both PHBV/PCL and PHBV/PCL/VEGF grafts were highly
porous (Figures 1A,B). However, PHBV/PCL grafts
consisted mostly of microscale fibers and large pores while
PHBV/PCL/VEGF grafts mainly constituted of nanoscale fibers
and small pores (Figures 1A,B). Quantitative image analysis
showed that PHBV/PCL/VEGF grafts had significantly lower
mean fiber diameter and mean pore area compared to their
unmodified counterparts (Figure 1B).
FIGURE 1 | Morphology of PHBV/PCL vascular grafts with and without VEGF. (A) Scanning electron microscopy images; (B) Quantitative image analysis (five
images containing in total >100 fibers and pores per group) showed that PHBV/PCL grafts with and without VEGF consisted mostly of nanoscale fibers/small pores
and microscale fibers/large pores, respectively. Moreover, it revealed a lower mean fiber diameter and mean pore area in PHBV/PCL grafts with VEGF compared to
those without. Data are represented as mean with standard deviation, ∗∗∗P < 0.001, two-tailed Student’s t-test.
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Incorporation of VEGF Significantly
Improves Physico-Mechanical Properties
of PHBV/PCL Vascular Grafts 6 Months
Postimplantation
In attempts to improve physico-mechanical properties of the
grafts, we suggested that tissues that gradually replace degrading
polymer may provide parameters similar to the native arteries.
Therefore, we also tested PHBV/PCL/VEGF grafts 6 months
postimplantation (Figure 2A) in addition to those before
the implantation. We revealed that durability, elasticity, and
stiffness of PHBV/PCL/VEGF grafts before the implantation
were respectively 2-, 2.41-, and 2.37-fold lower compared to
unmodified grafts but these values were still far from those
of IMA (Figures 2B–D). However, PHBV/PCL/VEGF grafts
explanted from rat abdominal aorta 6 months postimplantation
demonstrated durability and stiffness almost similar to IMA; in
addition, their elasticity and stress-strain curve were also closer
to IMA than before the implantation (Figures 2B–E).
Incorporation of VEGF Enhances
Endothelialization, Improves Patency,
and Recruits Cells to PHBV/PCL
Vascular Grafts
With the aim to compare endothelialization rate of PHBV/PCL
and PHBV/PCL/VEGF grafts, we stained grafts with (1)
hematoxylin and eosin; (2) antibodies to CD31, CD34, and
vWF which were previously defined as endothelial cell markers
(Hristov et al., 2003). One month postimplantation, histological
and immunohistochemical examination revealed a thrombus
occluding the graft lumen or intimal hyperplasia but no or
a few CD31-positive cells in all PHBV/PCL grafts (Figure 3).
However, 3/4 (75%) PHBV/PCL/VEGF grafts were patent and
had many CD31-positive cells at the inner surface (Figure 3).
In addition, we identified macrophages, fibroblasts, and collagen
fibers only in the outer third of PHBV/PCL grafts but in the
entire graft wall of PHBV/PCL/VEGF grafts. Confocal laser
scanning microscopy demonstrated that inner surface of all
PHBV/PCL grafts contained only a few CD31-, CD34, and
vWF-positive cells (Figure 4). However, we found many CD31-,
CD34-, and vWF-positive cells in 3/4 (75%) of PHBV/PCL/VEGF
grafts (Figure 4). Similar results were obtained 3 and 6 months
postimplantation. Moreover, combined vWF and DAPI staining
showed a significant increase in the total number of cells within
PHBV/PCL/VEGF compared to PHBV/PCL grafts 6 months
postimplantation. Quantitative image analysis confirmed the
findings from confocal laser scanning microscopy examination
(Figure 5).
DISCUSSION
High porosity of the vascular graft, nanoscale fiber diameter
and small pore area promote cell migration to the graft and
further formation of the endothelial cell monolayer after the
FIGURE 2 | Physico-mechanical properties of PHBV/PCL vascular grafts with and without VEGF. (A) Macroscopic images of PHBV/PCL grafts with VEGF
6 months postimplantation; (B) Incorporation of VEGF decreased durability of PHBV/PCL grafts almost to the values of internal mammary artery, particularly
6 months postimplantation; (C) Incorporation of VEGF reduced elasticity of PHBV/PCL grafts, particularly 6 months postimplantation; (D) Incorporation of VEGF
lowered stiffness of PHBV/PCL grafts, and 6 months postimplantation it was almost similar to the values of internal mammary artery; (E) Stress-strain curve of
PHBV/PCL grafts with VEGF was more similar to that of internal mammary artery, particularly 6 months postimplantation. Data are represented as median with
interquartile range, ∗∗P < 0.01, ∗∗∗P < 0.001, Mann–Whitney U-test.
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FIGURE 3 | In vivo performance of PHBV/PCL vascular grafts with and without VEGF: histological and immunohistochemical examination. PHBV/PCL
grafts with VEGF were completely patent whereas those without were occluded. Hematoxylin and eosin staining revealed a putative endothelial cell monolayer in
certain parts of the inner surface of PHBV/PCL grafts with VEGF even 1 month postimplantation and almost entire inner surface 3 and 6 months postimplantation.
This was confirmed by CD31 staining but was not the case for PHBV/PCL grafts without VEGF. CD31-positive cells are stained brown.
FIGURE 4 | In vivo performance of PHBV/PCL vascular grafts with and without VEGF: confocal laser scanning microscopy. PHBV/PCL grafts with VEGF
contained many CD31-, CD34-, and vWF-positive cells which therefore were defined as endothelial cells but this was not the case for unmodified grafts.
Furthermore, combined vWF- and DAPI staining revealed a significant increase in a total number of cells within the graft in PHBV/PCL/VEGF compared to
PHBV/PCL grafts 6 months postimplantation. Native rat abdominal aorta was used as a positive control. CD31-positive cells are stained red while CD34 and
vWF-positive cells are stained green. X, tr, in, gr, and ex are for neointima, thrombus, inner, middle, and upper third of the graft.
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FIGURE 5 | In vivo performance of PHBV/PCL vascular grafts with and without VEGF: quantitative image analysis. Quantitative image analysis (three
images per staining) confirmed an increase in number of CD31-, CD34, and vWF-positive cells in PHBV/PCL grafts with VEGF compared to those without after the
implantation into rat abdominal aorta. In addition, this approach verified the increase in a total number of cells within the graft in PHBV/PCL/VEGF compared to
PHBV/PCL grafts 6 months postimplantation. Data are represented as mean with standard deviation, ∗∗P < 0.01, two-tailed Student’s t-test.
implantation (Catto et al., 2014). These features of the polymer
scaffold make it similar to extracellular matrix (Catto et al.,
2014). Thin polymer fibers increase the area for the cell-scaffold
interactions that, in turn, enhances cell adhesion and further
cell metabolism (Sill and von Recum, 2008). This is of crucial
significance since cell infiltration of the graft wall improves
integration of the scaffold with the host tissue (Sachlos and
Czernuszka, 2003).
PHBV/PCL grafts with VEGF had a highly porous structure
and, in contrast to those without, consisted mostly of nanoscale
fibers and small pores. This can be explained by the presence of
water phase. Therefore, the composition of PHBV/PCL/VEGF
grafts was more similar to extracellular matrix compared to
unmodified grafts.
Physico-mechanical properties of PHBV/PCL grafts
significantly differed from those of native blood vessels;
however, incorporation of VEGF made them more similar
to those of IMA, and it was particularly significant 6 months
postimplantation. Thus, we suggest the absence of collagen,
elastin, and glycosaminoglycans as the cause of differences in
physico-mechanical properties between the polymer grafts before
implantation and IMA. This also corresponds to the literature
(L’Heureux et al., 2007).
Thrombosis and thromboembolism even despite
anticoagulant therapy are the main problems associated
with small-diameter synthetic vascular grafts (Tatterton et al.,
2012). The reasons for this are low blood flow in small-
diameter vessels and low thromboresistance of poly(ethylene
terephthalate) and ePTFE, which are currently used for the
preparation of synthetic vascular grafts (Tatterton et al., 2012).
Formation of the endothelial monolayer at the inner surface
of the vascular grafts may improve their long-term patency
(L’Heureux et al., 1998). Previously, we detected an endothelial
cell monolayer in only one-fourth of PHBV/PCL vascular grafts
1 year postimplantation using rat abdominal aorta replacement
model as here (Antonova et al., 2015a). In this study, all
unmodified grafts were occluded or had the signs of neointima
formation. In contrast, three-fourths of PHBV/PCL/VEGF
vascular grafts were completely patent and had an endothelial
cell monolayer even 6 months postimplantation. Moreover,
incorporation of VEGF enhanced migration of CD34-positive
cells to the graft. This is of particular importance since CD34
is a marker of endothelial progenitor cells, and migration
of CD34-positive cells to the vascular graft was previously
observed both in vitro (Boyer et al., 2000) and in vivo (De
Visscher et al., 2012). In addition, we found that incorporation
of VEGF led to an increase of the total number of cells
within the graft. Therefore, we suggest that VEGF promotes
endothelialization and improves patency of the vascular graft
in vivo.
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Our data demonstrate that incorporation of VEGF improves
biofunctionalization of PHBV/PCL vascular grafts. It makes graft
more similar to extracellular matrix and brings its physico-
mechanical properties closer to those of IMA. Furthermore, it
stimulates migration of cells to the graft, promotes formation
of endothelial cell monolayer in situ, and improves graft
patency.
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